Cargando…
Regulatory analysis on the medical use of ephedrine-related products in Taiwan
To prevent ephedrine-related products from being misused to produce amphetamine and/ or its analogs, there's a need for more effective and achievable regulatory mechanisms for the health, police, investigational, prosecution and judiciary authorities in Taiwan. This review was conducted to eval...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taiwan Food and Drug Administration
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322211/ https://www.ncbi.nlm.nih.gov/pubmed/29567216 http://dx.doi.org/10.1016/j.jfda.2017.11.002 |
_version_ | 1784756242625855488 |
---|---|
author | Yu, Wan-Nan Wang, Li-Hsuan Cheng, Hui-Wen |
author_facet | Yu, Wan-Nan Wang, Li-Hsuan Cheng, Hui-Wen |
author_sort | Yu, Wan-Nan |
collection | PubMed |
description | To prevent ephedrine-related products from being misused to produce amphetamine and/ or its analogs, there's a need for more effective and achievable regulatory mechanisms for the health, police, investigational, prosecution and judiciary authorities in Taiwan. This review was conducted to evaluate the international and Taiwan's regulatory policies and management of medical ephedrine-related products through the corresponding information collected from international and Taiwan government agency authorities. The combat of illegal drugs should involve both supply and demand sides to be successful. Health authorities in Taiwan do not have the investigational power to manage the forbidden transformation, abusing and manufacture of the illegal drugs from ephedrine-related products. Take the judicial interventions in the United States and in Japan as the examples, the organizational cooperation in Taiwan can be one of the main key strategies to combat against illegal drugs from ephedrine-related products. It is necessary to integrate the judicial, police and health agencies to prevent the production of illegal drugs from the ephedrine-related products in Taiwan. The efforts and regulatory control measures should be integrated to speed up the collaboration between different government authorities. It might be achieved through reorganization involving Taiwan Food and Drug Administration. |
format | Online Article Text |
id | pubmed-9322211 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taiwan Food and Drug Administration |
record_format | MEDLINE/PubMed |
spelling | pubmed-93222112022-08-09 Regulatory analysis on the medical use of ephedrine-related products in Taiwan Yu, Wan-Nan Wang, Li-Hsuan Cheng, Hui-Wen J Food Drug Anal Review Article To prevent ephedrine-related products from being misused to produce amphetamine and/ or its analogs, there's a need for more effective and achievable regulatory mechanisms for the health, police, investigational, prosecution and judiciary authorities in Taiwan. This review was conducted to evaluate the international and Taiwan's regulatory policies and management of medical ephedrine-related products through the corresponding information collected from international and Taiwan government agency authorities. The combat of illegal drugs should involve both supply and demand sides to be successful. Health authorities in Taiwan do not have the investigational power to manage the forbidden transformation, abusing and manufacture of the illegal drugs from ephedrine-related products. Take the judicial interventions in the United States and in Japan as the examples, the organizational cooperation in Taiwan can be one of the main key strategies to combat against illegal drugs from ephedrine-related products. It is necessary to integrate the judicial, police and health agencies to prevent the production of illegal drugs from the ephedrine-related products in Taiwan. The efforts and regulatory control measures should be integrated to speed up the collaboration between different government authorities. It might be achieved through reorganization involving Taiwan Food and Drug Administration. Taiwan Food and Drug Administration 2017-12-02 /pmc/articles/PMC9322211/ /pubmed/29567216 http://dx.doi.org/10.1016/j.jfda.2017.11.002 Text en © 2018 Taiwan Food and Drug Administration https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Review Article Yu, Wan-Nan Wang, Li-Hsuan Cheng, Hui-Wen Regulatory analysis on the medical use of ephedrine-related products in Taiwan |
title | Regulatory analysis on the medical use of ephedrine-related products in Taiwan |
title_full | Regulatory analysis on the medical use of ephedrine-related products in Taiwan |
title_fullStr | Regulatory analysis on the medical use of ephedrine-related products in Taiwan |
title_full_unstemmed | Regulatory analysis on the medical use of ephedrine-related products in Taiwan |
title_short | Regulatory analysis on the medical use of ephedrine-related products in Taiwan |
title_sort | regulatory analysis on the medical use of ephedrine-related products in taiwan |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322211/ https://www.ncbi.nlm.nih.gov/pubmed/29567216 http://dx.doi.org/10.1016/j.jfda.2017.11.002 |
work_keys_str_mv | AT yuwannan regulatoryanalysisonthemedicaluseofephedrinerelatedproductsintaiwan AT wanglihsuan regulatoryanalysisonthemedicaluseofephedrinerelatedproductsintaiwan AT chenghuiwen regulatoryanalysisonthemedicaluseofephedrinerelatedproductsintaiwan |